Vitamin D3 for Life

Live Enlightened

Article

Enzymatic inactivation pathways of vitamin D metabolites: Full Evidence Review

Previous related pageEarly-Life Vitamin D and Childhood Immune Trajectories: Full Evidence ReviewNext related pageEnzymatic inactivation pathways of vitamin D metabolites: Study Summary
Study at a glance

How did researchers study vitamin D breakdown?

This page describes three types of research into how the body breaks down vitamin D. Scientists changed an enzyme called CYP24A1 in the laboratory, studied rats that could not make this enzyme, and examined rare inherited changes in people. An enzyme is a protein that helps chemical reactions happen.

What did changing the vitamin D breakdown enzyme show?

CYP24A1 helps break down both active vitamin D and the form that can be turned into active vitamin D. It does this through a series of chemical steps. Changing one part of the enzyme, called residue 326, changed which breakdown route it favoured. Rats without the enzyme had higher blood levels of 25-hydroxyvitamin D after receiving it, and made much less of several breakdown products. In people, rare inherited faults in this enzyme were linked to unusually high calcium levels in infancy.

What do these findings tell us about vitamin D removal?

Breaking down vitamin D helps the body control its effects and calcium levels. Other enzymes may help with some of the final steps. Laboratory tests, rats and rare human diseases provide different kinds of evidence, so their results cannot be treated as the same. These studies do not tell us exactly how quickly the whole human body clears vitamin D.

Read the full article below ↓

Why vitamin D inactivation is a pathway rather than a single reaction

Vitamin D signalling is terminated and reshaped through oxidative metabolism, not by one simple disposal step. CYP24A1 is the central mitochondrial cytochrome P450 in this process. The broader relationship between CYP27B1 and CYP24A1 enzyme pathways places this catabolic arm alongside vitamin D activation. It can act on both 25-hydroxyvitamin D [25(OH)D] and the active hormone 1,25-dihydroxyvitamin D [1,25(OH)2D], progressively oxidising their side chains and reducing the persistence of substrates that would otherwise remain available for activation or receptor signalling.

The key mechanistic point is that CYP24A1 is not accurately described as only a 24-hydroxylase. Human CYP24A1 can initiate at different side-chain carbons and support distinct C24: and C23-oxidation routes. These routes share an enzyme but do not represent one chemically uniform pathway.

What Prosser and colleagues tested

Prosser and colleagues used CYP24A1 expression systems, site-directed mutagenesis and metabolite analysis to ask why human and opossum enzymes show different regioselectivity. Human CYP24A1 normally favours C24 oxidation, whereas the opossum enzyme has greater C23-hydroxylase activity. Sequence comparison identified candidate active-site differences, including residue 326.

The investigators replaced alanine 326 in human CYP24A1 with glycine. That single A326G substitution markedly shifted the human enzyme away from its usual C24 preference and toward C23 hydroxylation, generating 26,23-lactone pathway products. The experiment therefore connected a defined structural change in the enzyme with a change in metabolic route.

C24 oxidation is a sequential catabolic programme

The C24 route is best understood as a sequence of oxidation reactions rather than one hydroxylation event. CYP24A1 first introduces a hydroxyl group at carbon 24 and can continue oxidising the side chain through progressively more oxidised intermediates. For 1,25(OH)2D3, this route ultimately supports formation of shortened, water-soluble catabolic products including calcitroic acid.

This sequential behaviour matters physiologically because enzyme abundance and catalytic access influence how long 25(OH)D remains available for activation and how long 1,25(OH)2D remains available to engage the vitamin D receptor. Clearance therefore acts on both the precursor pool and the active-hormone pool, linking directly to vitamin D metabolism at the cellular level.

The C23 branch is chemically distinct

The alternative C23 route begins with hydroxylation at carbon 23 and can progress toward side-chain lactonisation. Prosser’s structural work showed that the choice between the C24 and C23 routes is not arbitrary. The architecture of the substrate-binding environment helps orient the vitamin D side chain relative to the catalytic centre, changing which carbon is attacked.

That finding also explains why species differences cannot simply be treated as interchangeable human physiology. Different CYP24A1 orthologues can favour different routes even when they act on the same vitamin D substrate.

Knockout evidence tests which metabolites actually require CYP24A1

Yasuda and colleagues moved the question from recombinant enzyme systems into an intact animal. Using CRISPR/Cas9-generated Cyp24a1-knockout rats, they administered 25(OH)D3 and followed circulating metabolites. Loss of Cyp24a1 markedly increased plasma 25(OH)D3 and abolished or strongly reduced several downstream oxidative metabolites.

This is important causal evidence because it shows that CYP24A1 materially controls the in-vivo disappearance and metabolic branching of 25(OH)D3. The enzyme is not merely capable of producing catabolites in vitro; its absence changes the circulating metabolite profile.

Why the terminal lactone step needs qualification

The knockout work also prevented an over-simple CYP24A1-only model of the C23 branch. Yasuda and colleagues found evidence that formation of the terminal 26,23-lactone could involve CYP3A activity, particularly in the conversion of a later tri-hydroxylated intermediate. That means CYP24A1 can be essential to establishing the upstream C23 pathway without necessarily being the sole enzyme responsible for every terminal reaction.

The appropriate conclusion is therefore pathway-level rather than enzyme-exclusive: CYP24A1 initiates and drives major oxidative branches of vitamin D catabolism, but at least some later transformations may involve additional cytochrome P450 enzymes.

Human loss of function shows why degradation matters

Rare human CYP24A1 deficiency supplies a very different kind of evidence. Schlingmann and colleagues identified recessive CYP24A1 mutations in idiopathic infantile hypercalcaemia and demonstrated major loss of enzyme function. Affected individuals can become unusually sensitive to vitamin D exposure because catabolic restraint is impaired.

This genetic evidence strengthens the physiological interpretation of the biochemical pathway. If CYP24A1-mediated degradation were merely a chemically interesting side route, loss of the enzyme would not be expected to cause a clinically important disturbance of calcium and vitamin D homeostasis. The human phenotype shows that controlled inactivation is part of the protective architecture of the system.

What this evidence establishes and what it does not

  • CYP24A1 is a multicatalytic vitamin D catabolic enzyme, not simply a one-step 24-hydroxylase.
  • Human CYP24A1 can support both C24: and C23-oxidation pathways.
  • Active-site structure can materially alter pathway regioselectivity.
  • Cyp24a1 loss causes major changes in 25(OH)D metabolite profiles in vivo.
  • Some terminal C23/lactone chemistry may involve CYP3A or other enzymes rather than CYP24A1 alone.
  • Rare human CYP24A1 loss of function confirms that degradation materially protects vitamin D and calcium homeostasis.

These experiments do not provide a single quantitative whole-body human clearance rate. Recombinant enzyme studies define catalytic mechanism, knockout rodents define causal in-vivo dependence, and rare human genetics demonstrates physiological necessity. Their evidential jobs are complementary rather than interchangeable.

Primary evidence and publication details

Prosser DE, Kaufmann M, O’Leary B, Byford V, Jones G. Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone. Proc Natl Acad Sci U S A. 2007;104:12673-12678.

Yasuda K, Nishikawa M, Okamoto K, et al. Elucidation of metabolic pathways of 25-hydroxyvitamin D3 mediated by CYP24A1 and CYP3A using Cyp24a1 knockout rats generated by CRISPR/Cas9 system. J Biol Chem. 2021;296:100668.

Schlingmann KP, Kaufmann M, Weber S, et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med. 2011;365:410-421.

Related reading

Physiology

Vitamin D and Calcium

Learn how vitamin D supports calcium regulation by influencing absorption, kidney handling, hormonal coordination, and wider physiological balance.

Read more →

Original sources